Targeting apoptosis pathways in lung cancer |
| |
Authors: | Milind M. Pore T. Jeroen N. Hiltermann Frank A.E. Kruyt |
| |
Affiliation: | 1. Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands;2. Department of Pulmonology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands |
| |
Abstract: | Lung cancer is a devastating disease with a poor prognosis. Non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) represent different forms of lung cancer that are associated with distinct genetic causes and display different responses to therapy in the clinic. Whereas SCLC is often sensitive to chemotherapy at start of treatment, NSCLC are less chemo-sensitive. In NSCLC different histological subtypes are distinguished and increasing efforts are made to identify subtypes that respond to specific therapies, such as those harbouring epidermal growth factor receptor (EGFR) mutations that have benefit from treatment with EGFR inhibitors. Targeting of the apoptotic machinery represents another approach that aims to selectively kill cancer cells while sparing normal ones. Here we describe different ways that are currently explored to induce apoptosis in lung cancer cells, specifically pathways controlled by TNF-related apoptosis-inducing ligand (TRAIL), BCL-2 family members and apoptosis inhibitory proteins (IAPs). Preclinical studies are discussed and for some agents results from early clinical studies and future perspectives are considered. |
| |
Keywords: | Lung cancer Apoptosis TRAIL XIAP Survivin BCL-2 Therapy |
本文献已被 ScienceDirect 等数据库收录! |
|